This CardiaCast episode explores the latest advances in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at ACC.26, with a focused review of newly released late-stage clinical trial data for currently available disease-modifying therapies. Expert faculty Drs. Sarah Cuddy and Prem Soman break down how emerging evidence is reshaping treatment selection, including considerations for efficacy, safety, and patient-specific factors. The discussion highlights practical strategies for integrating these new findings into real-world clinical practice to optimize outcomes for patients with ATTR-CM.

This podcast is developed by the American College of Cardiology Foundation and Med-IQ and supported by an educational grant from Bridge Bio.

Related References:

1. Soman P, Gillmore JD, Goodman H, et al. Long-term survival benefits and disease stabilization with acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Presented at American College of Cardiology Scientific Sessions in New Orleans, LA, March 2026.
2. Cuddy S, Pavia PG, Fernandes F, et al. Post hoc analysis of diastolic dysfunction in the HELIOS-B study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. J Am Coll Cardiol. 2026;87(13 suppl):abstract. doi:10.1016/j.jacc.2026.02.1486
3. Griffin JM, Fontana M, Mitchell JD, et al. Association between early increase in serum transthyretin (sTTR) with acoramidis and long-term effects on heart failure-related health status in transthyretin amyloid cardiomyopathy (ATTR-CM): results from ATTRibute-CM. J Am Coll Cardiol. 2026;87(13 suppl):abstract. doi:10.1016/j.jacc.2026.02.1552
4. Writing Committee, Kittleson MM, Ambardekar AV, et al. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. J Am Coll Cardiol. 2026;87(5):549-565. doi:10.1016/j.jacc.2025.09.004